Healthcare
Anbio Biotechnology Class A Ordinary Shares(NNNN)
Live Price
Offline$16.47
-1.02% today
1Y Change
-48.26%
Window
Jun 25, 2025 โ Jun 22, 2026
- Market Cap
- $1.27B
- Revenue Growth
- +5.6%
- EPS Growth
- +185.7%
- Dividend Yield
- 0.0%
Coverage: 248 bars ยท Jun 25, 2025 โ Jun 22, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Anbio Biotechnology Class A Ordinary Shares (NNNN) is a Healthcare stock with a market cap of $1.27B and listed on NASDAQ. The stock last traded around $16.47 and down 48.3% across the available one-year price window (Jun 25, 2025 โ Jun 22, 2026). Baseline metrics include revenue growth of +5.6%, EPS growth of +185.7%, a dividend yield of 0.0%. What stands out right now is revenue +5.6%, EPS +185.7%, free cash flow -423.9% with operating margin 66.5% and ROIC 21.5%. Valuation already assumes a fairly strong business story at P/E 176.5 and price/sales 130.2. Stock Foundry combines NNNN price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
+5.6% vs +7.6% peer median
Operating Margin
Above sector median
+66.5% vs +19.4% peer median
P/E
Above sector median
176.5 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Apr 7, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +5.6% and EPS at +185.7%, with operating margin around 66.5%.
Benchmark Edge
NNNN vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
NNNN
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
NNNN Max Drawdown
-76.41%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for NNNN and SPY.
Company Overview
Anbio Biotechnology Class A Ordinary Shares
NASDAQ Global Select
Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, Africa, and internationally. It offers SARS-CoV-2 antigen rapid and SARS-CoV-2/influenza A/B antigen rapid tests; and lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, chemiluminescence immunoassay, and reverse-transcription polymerase chain reaction products. It serves over-the-counter, point-of-care testing, and laboratory markets. The company was incorporated in 2021 and is based in Frankfurt am Main, Germany.
- Leadership
- Michael Lau
- IPO Date
- Feb 19, 2025
- Employees
- 27
- Street Address
- Wilhelm Gutbrod Str 21B
- Mailing
- Frankfurt am Main, 60437
- Region
- Frankfurt am Main, DE
- Reporting Currency
- USD
- Investor Line
- 49 16 0962 47281
- Last Updated
- May 2, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 176.5
- EV/EBITDA
- 181.5
- Price/Sales
- 130.2
- Price/Book
- 42.1
Growth
- Revenue
- +5.6%
- EPS
- +185.7%
- Free Cash Flow
- -423.9%
Profitability
- Gross Margin
- 87.1%
- Operating Margin
- 66.5%
- Net Margin
- 73.7%
- ROE
- 23.0%
- ROIC
- 21.5%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 344.31
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.